Compare RAVE & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | NNVC |
|---|---|---|
| Founded | 1958 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 37.9M |
| IPO Year | 1995 | 2008 |
| Metric | RAVE | NNVC |
|---|---|---|
| Price | $3.07 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 321.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | 10.00 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $15,120,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.25 | $0.85 |
| 52 Week High | $3.75 | $2.23 |
| Indicator | RAVE | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 39.11 |
| Support Level | $3.03 | $1.24 |
| Resistance Level | $3.13 | $1.47 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 19.53 | 13.89 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.